Compare DUOT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | IVVD |
|---|---|---|
| Founded | 1990 | 2020 |
| Country | United States | United States |
| Employees | N/A | 122 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.2M | 219.9M |
| IPO Year | 2017 | 2021 |
| Metric | DUOT | IVVD |
|---|---|---|
| Price | $8.86 | $1.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $17.00 | $8.75 |
| AVG Volume (30 Days) | 685.0K | ★ 3.6M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.96 | ★ 79.02 |
| EPS | ★ 1.37 | N/A |
| Revenue | $27,023,651.00 | ★ $53,426,000.00 |
| Revenue This Year | $50.98 | $61.57 |
| Revenue Next Year | N/A | $41.42 |
| P/E Ratio | $6.24 | ★ N/A |
| Revenue Growth | ★ 271.16 | 110.47 |
| 52 Week Low | $6.17 | $0.53 |
| 52 Week High | $15.28 | $3.07 |
| Indicator | DUOT | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 61.80 |
| Support Level | $8.04 | $0.71 |
| Resistance Level | $9.52 | $1.02 |
| Average True Range (ATR) | 0.36 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 76.23 | 79.38 |
Duos Technologies Group Inc delivers AI-driven technologies, edge computing infrastructure, and energy consulting services to support data-intensive and mission-critical operations. It manages, operates, engineers, software development, customer support and project implementation and management across three market segments, including rail technology deployment, Data Center co-location facilities, and behind-the-meter electrical power provision. It also continues to operate as a technology company which designs, develops, deploys, and operates intelligent technology solutions with a focus on software applications and artificial intelligence (AI) in addition to large projects, consulting, implementation, and asset management.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.